Poster
T-DXd
ESMO Breast 2025 | May 14-17, 2025
Breast Cancer
Chemotherapy outcomes in human epidermal growth factor receptor 2 (HER2)‑low, hormone receptor positive (HR+) metastatic breast cancer (mBC): Insights from the French multicenter ESME database
William Jacot
Mini-Oral
T-DXd
ESMO Breast 2025 | May 14-17, 2025
Breast Cancer
DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
Carlos H. Barrios
Poster
T-DXd
ESMO Breast 2025 | May 14-17, 2025
Breast Cancer
Human epidermal growth factor receptor-2 (HER2)-directed therapies administered after trastuzumab deruxtecan (T-DXd) retain efficacy in patients with metastatic breast cancer (mBC): Exploratory analysis of the DESTINY-Breast02 and -03 trials
Peter A. Fasching
Poster
Other/Multi
ESMO Breast 2025 | May 14-17, 2025
Breast Cancer
Treatment patterns, overall survival (OS), and healthcare resource utilization (HCRU) among Patients with HER2-positive (HER2+), high- or intermediate-risk, early-stage breast cancer (eBC) in Canada
Winson Cheung